Positron-Emission Tomographic Scanning of Primary and Metastatic Breast Carcinoma with the Radiolabeled Glucose Analogue 2-Deoxy-2-[18F]Fluoro-d-Glucose

Publisher Website
Google Scholar
Abstract
Currently, no single imaging technique reliably detects both primary and metastatic foci of breast cancer.1 2 3 We wish to report the feasibility of simultaneously imaging primary and metastatic breast cancer using a whole-body positron-emission tomographic (PET) scanning device. The whole-body PET scanner uses multiple rings of radiation detectors and computerized reconstruction algorithms to generate images of the in vivo distribution of radioactivity in a patient.4 In this case, breast-cancer imaging was achieved by determining in the vivo biodistribution of an intravenously administered cyclotron-produced Radio-labeled glucose analogue, 2-deoxy-2-[18F]fluoro-D-glucose (FDG).5